BRPI0416105A - uso da bh4 para o tratamento de doença respiratórias - Google Patents

uso da bh4 para o tratamento de doença respiratórias

Info

Publication number
BRPI0416105A
BRPI0416105A BRPI0416105-0A BRPI0416105A BRPI0416105A BR PI0416105 A BRPI0416105 A BR PI0416105A BR PI0416105 A BRPI0416105 A BR PI0416105A BR PI0416105 A BRPI0416105 A BR PI0416105A
Authority
BR
Brazil
Prior art keywords
treatment
respiratory disease
derivatives
tetrahydrobiopterin
copd
Prior art date
Application number
BRPI0416105-0A
Other languages
English (en)
Inventor
Christian Hesslinger
Christian Schudt
Wolf-Ruediger Ulrich
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of BRPI0416105A publication Critical patent/BRPI0416105A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"USO DA BH4 PARA O TRATAMENTO DE DOENçAS RESPIRATóRIAS". A invenção descreve o uso de tetrahidrobiopterina (BH4) ou de derivados da mesma no tratamento de COPD. Em uma modalidade preferida, a BH4 ou os derivados da mesma são combinados com a arginina ou com derivados da mesma.
BRPI0416105-0A 2003-10-31 2004-10-29 uso da bh4 para o tratamento de doença respiratórias BRPI0416105A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03024844 2003-10-31
PCT/EP2004/052725 WO2005041975A1 (en) 2003-10-31 2004-10-29 Use of bh4 for the treatment of respiratory diseases

Publications (1)

Publication Number Publication Date
BRPI0416105A true BRPI0416105A (pt) 2007-01-02

Family

ID=34530659

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416105-0A BRPI0416105A (pt) 2003-10-31 2004-10-29 uso da bh4 para o tratamento de doença respiratórias

Country Status (13)

Country Link
US (1) US20070049599A1 (pt)
EP (1) EP1682148A1 (pt)
JP (1) JP2007509909A (pt)
KR (1) KR20060120147A (pt)
CN (1) CN1871011A (pt)
AU (1) AU2004285300A1 (pt)
BR (1) BRPI0416105A (pt)
CA (1) CA2543252A1 (pt)
IL (1) IL174589A0 (pt)
MX (1) MXPA06004687A (pt)
NO (1) NO20062384L (pt)
WO (1) WO2005041975A1 (pt)
ZA (1) ZA200602536B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006120176A2 (en) * 2005-05-11 2006-11-16 Nycomed Gmbh Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative
CN103988080B (zh) * 2011-10-11 2016-06-08 加利福尼亚大学董事会 用于腹主动脉瘤的生物标记物
EP3548497A4 (en) 2016-11-29 2020-09-02 Censa Pharmaceuticals Inc. SEPIAPTERIN POLYMORPHS AND THEIR SALTS
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
EP3675863A4 (en) 2017-09-01 2021-01-27 PTC Therapeutics MP, Inc. PHARMACEUTICAL COMPOSITIONS WITH SEPIAPTERIN AND USES THEREOF
US20240115573A1 (en) * 2021-03-26 2024-04-11 Emory University Managing the Acute and Long-Term Effects of Coronaviral Infections and Compositions Related Thereto

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877176A (en) * 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
US5830461A (en) * 1992-11-25 1998-11-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods for promoting wound healing and treating transplant-associated vasculopathy
DE4418097A1 (de) * 1994-05-24 1995-11-30 Cassella Ag Verwendung von Tetrahydropteridin-Derivaten als Hemmstoffe der NO-Synthase
AU2896695A (en) * 1994-07-14 1996-02-16 Glaxo Wellcome House Nitric oxide synthase inhibitors for inhibiting the production of airway mucus
WO1998008516A1 (en) * 1996-08-30 1998-03-05 Suntory Limited Preventives or remedies for diseases induced by hypofunction of nitric oxide synthase (nos)
SE0000307D0 (sv) * 2000-01-31 2000-01-31 Univ Zuerich Method and formulation för treatment of vasoconstriction
US6544994B2 (en) * 2000-06-07 2003-04-08 Eprov Ag Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase
US20040087653A1 (en) * 2002-05-16 2004-05-06 Manning Pamela T. Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor
US20040097467A1 (en) * 2002-08-22 2004-05-20 Vijaya Juturu Arginine silicate inositol complex and use thereof

Also Published As

Publication number Publication date
CN1871011A (zh) 2006-11-29
EP1682148A1 (en) 2006-07-26
NO20062384L (no) 2006-05-24
US20070049599A1 (en) 2007-03-01
AU2004285300A1 (en) 2005-05-12
IL174589A0 (en) 2006-08-20
ZA200602536B (en) 2007-06-27
MXPA06004687A (es) 2006-06-27
KR20060120147A (ko) 2006-11-24
JP2007509909A (ja) 2007-04-19
CA2543252A1 (en) 2005-05-12
WO2005041975A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
ATE408601T1 (de) Fredericamycin-derivate
IL199914B (en) Use of protein kinase n beta for the manufacture of a diagnostic agent
DOP2002000429A (es) Imidazotriazinas
WO2003080582A3 (de) Fredericamycin-derivate
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
CL2004001069A1 (es) Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
DK1377589T3 (da) Oxazolyl-pyrazolderivater som kinaseinhibitorer
LTC1425001I2 (lt) Fenetanolamino dariniai, skirti kvėpavimo ligoms gydyti
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
GT200100183A (es) Derivados de quinolina y quinazolina.
EE200300409A (et) Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
IS7814A (is) Fenetanólamín afleiða í meðhöndlun á öndunarfærasjúkdómum.
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
BRPI0407234A (pt) Heterociclos substituìdos
SE0301653D0 (sv) Novel compounds
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
BRPI0410633A (pt) piridopirazinas e uso das mesmas como moduladores de cinase
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
BRPI0410986A (pt) derivados de estaurosporina para sìndrome hipereosinofìlica
ATE410148T1 (de) Pharmazeutische zubereitung zur oralen verwendung von heparin und seinen derivaten
BRPI0416105A (pt) uso da bh4 para o tratamento de doença respiratórias
DE602007010038D1 (de) Pyrimidylderivate als proteinkinaseinhibitoren

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. 461K 31/519, A61K 31/195, A61P 11/00

Ipc: A61K 31/519 (2011.01), A61K 31/195 (2011.01), A61P

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.